PROMOGRAN® is sterile, freeze-dried composite of 55% collagen and 45% oxidised regenerated cellulose (ORC).
PROMOGRAN® is designed to promote an optimal healing environment1
With PROMOGRAN® stalled wounds close:
• Cost Effectively1,3,4
In the presence of exudate the PROMOGRAN® protease modulating matrix transforms into a soft and conformable, biodegradable gel: this allows contact with all areas of the wound.
Click this link to view PROMOGRAN® product codes
- Early adoption of Collagen/ORC therapies improves venous leg ulcers and diabetic foot ulcers
- EPA modulating therapies: the ability of collagen/ORC to reduce EPA and facilitate healing
The product information on this page is not intended to be used by health care professinoals or users in the United States and may not comply with the regulatory standards of the United States – please click the link above for product information in respect of products used in the United States
© Systagenix Wound Management 2011. Brands marked with ® or ™ are trademarks of Systagenix. All other products referenced herein are acknowledged to be trademarks of their respective owners.
3. Snyder. Sequential therapies and advanced wound care products as a standard practice in the home care setting. Home health abstract for SAWC, San Diego, April 2008 (presentation at the J&J satellite symposium)
4. Ghatenekar O. Willis. M. Persson U. Health Economics. ‘Cost effectiveness of treating deep diabetic foot ulcers with collagen/ORC in four European countries’. J Wound Care, Vol 11, No2. Feb 2002
5. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L. Mechanism of action of Collagen/ORC, a protease modulating matrix for treatment of diabetic foot ulcers. Wound Rep Regen 2002;10:16-25.
11. Cullen, B., Kemp, L., Essler, L. Rebalancing wound biochemistry improves healing: a clinical study examining effect of PROMOGRAN. Wound Repair Regen. 2004 12(2) A4.
12. Cullen et al. A comparison of collagen containing dressings to modify the chronic wound environment. EWMA 2007
13. Cullen, B., Boyle, C., Webb, Y. Modulation of the chronic wound environment; an in vitro evaluation of advanced wound therapies. SAWC, Tampa FL, 2007.